Importantly, tumor cells from patients with EGFR mutation showed increased expression of several MHC class I and II genes compared to tumor cells from patients with KRAS mutant tumors, along with an increase in CD74, which regulates the presentation of MHC class II proteins (Fig. 2i). This evidence concerns the gene KRAS and neoplasm.